El ‘médico rural’ que transformó nuestra manera de ver la demencianews2024-09-14T09:03:22+00:00September 14th, 2024|The New York Times|
Francisco Lopera, the ‘Country Doctor’ Who Upended Our Understanding of Dementianews2024-09-11T14:07:34+00:00September 11th, 2024|The New York Times|
Executives Depart Cassava, Maker of Disputed Alzheimer’s Drugnews2024-07-18T22:21:49+00:00July 18th, 2024|The New York Times|
FDA Approves Donanemab, Eli Lilly’s New Drug for Early Alzheimer’snews2024-07-02T18:58:44+00:00July 2nd, 2024|The New York Times|
Embattled Alzheimer’s Researcher Is Charged With Fraudnews2024-06-28T22:05:18+00:00June 28th, 2024|The New York Times|
Hace casi un año se aprobó un fármaco para frenar el alzhéimer. ¿Ha funcionado?news2024-06-17T21:59:44+00:00June 17th, 2024|The New York Times|
FDA Advisory Panel Endorses Approval of Alzheimer’s Drug Made by Eli Lillynews2024-06-10T21:05:19+00:00June 10th, 2024|The New York Times|
Leqembi and Alzheimer’s: What to Know About the New Drug, Treatment and Benefitsnews2024-06-10T09:00:35+00:00June 10th, 2024|The New York Times|
Study Suggests Genetics as a Cause, Not Just a Risk, for Some Alzheimer’snews2024-05-06T16:19:15+00:00May 6th, 2024|The New York Times|
F.D.A. Delays Action on Closely Watched Alzheimer’s Drugnews2024-03-08T11:45:07+00:00March 8th, 2024|The New York Times|
